Poland is considering a new national reserve of critical medicines, aiming to secure a six-month supply by utilizing the country’s existing pharmaceutical wholesale network. The proposal, discussed at President Karol Nawrocki’s first Health Council meeting, seeks to address vulnerabilities in the supply chain.
Addressing Supply Chain Weaknesses
The initiative comes as Poland currently relies on Asian sources for approximately 80% of its active pharmaceutical ingredients (APIs). Experts have warned that Poland’s ability to guarantee consistent access to necessary medications – termed “drug security” – is at risk without a more resilient supply chain. This includes everything from API production to final distribution.
The plan focuses on medicines listed on both Poland’s national critical medicines list and the EU’s Union list, including essential drugs like antibiotics, anesthetics, and those used to treat cardiovascular conditions.
Wholesalers as a Key Component
Rather than constructing new storage facilities, the proposal suggests leveraging existing infrastructure. Łukasz Pietrzak, chief pharmaceutical inspector, argued that partnering with pharmaceutical wholesalers – firms already equipped with specialized logistics – would be a “faster and most cost-effective” approach. Andrzej Stachnik, president of the Association of Pharmaceutical Wholesalers (ZPHF), affirmed the sector’s readiness to establish “rotating reserves” using Polish firms and capital.
Funding for this initiative could potentially come from the Bank Gospodarstwa Krajowego, according to Stachnik. The model is inspired by a successful approach already implemented in Finland.
The Debate Over Domestic Production
While welcoming the stockpiling proposal, Krzysztof Kopeć, president of Medicines for Poland, emphasized the importance of bolstering domestic production. He cautioned that stockpiling alone is insufficient, stating, “It’s hard to stockpile supplies of all critical medicines.” Kopeć highlighted the World Health Organization’s (WHO) focus on reliable supply chains through local manufacturing. He also pointed to France’s unsuccessful attempt to build API production capacity, citing price disadvantages compared to Asian imports.
Kopeć argued that increasing EU production of critical drugs requires guaranteed sales at profitable prices, potentially necessitating higher costs for buyers. He suggested Poland could collaborate with neighboring countries like Lithuania and Latvia to expand the market for domestically produced medicines, ultimately prioritizing national security and resilience over cheaper imports.
Frequently Asked Questions
What is the primary goal of Poland’s proposed medicine reserve?
The primary goal is to shield Poland against potential shortages of critical medicines by establishing a six-month supply, utilizing the existing wholesale network.
What concerns has been raised regarding the proposal?
Concerns have been raised that the proposal is at too early a stage to assess against European standards and that stockpiling alone is not enough, with a greater focus needed on domestic production.
What role are pharmaceutical wholesalers expected to play?
Pharmaceutical wholesalers are expected to hold the buffer stock of critical medicines, leveraging their existing logistics and infrastructure to create rotating reserves.
As Poland considers this new approach to drug security, will prioritizing domestic production and regional collaboration prove to be a viable path toward greater independence from global supply chain vulnerabilities?
